PGT in IVF: Genetic Testing for Healthier Babies

Preimplantation genetic testing (PGT) enhances IVF success by screening embryos for genetic defects, reducing miscarriage risk by 30% and increasing live birth rates. This technology allows for early detection of abnormalities like Down syndrome, enabling couples to select healthy embryos for implantation. While PGT is not mandatory for all IVF cases, it’s critical for those with genetic disorders or recurrent implantation failures.

Key Takeaways

PGT Benefits: Reducing Genetic Risks and Improving IVF Success Rates

PGT identifies embryos with chromosomal abnormalities, such as trisomy 21 (Down syndrome), and selects euploid embryos for implantation. Studies show PGT-A (aneuploidy screening) can boost live birth rates by 20-30% in women over 35.

How PGT Works: Embryo Genetic Screening for Defect Detection

A biopsy of 5-10 cells is taken from the embryo at the blastocyst stage (day 5-6) and analyzed using next-generation sequencing. This process identifies single-gene disorders (PGT-M) or structural rearrangements (PGT-SR) without affecting embryo viability.

PGT Limitations: Understanding Misdiagnosis Risks and Ethical Dilemmas

Despite its benefits, PGT has a 1-2% false-positive rate, potentially discarding viable embryos. Ethical debates also arise around ‘designer baby’ concerns, though current guidelines restrict PGT to medical rather than cosmetic purposes.

Ethical Considerations of PGT in IVF: Balancing Medical and Moral Implications

PGT raises questions about genetic discrimination and societal equity, as access to testing remains limited by cost. Regulatory bodies emphasize transparency, counseling, and non-discrimination policies to address these challenges.

Future of PGT: Gene Editing and Enhanced Genetic Screening for IVF

Emerging technologies like CRISPR-Cas9 may enable precise gene correction in embryos. AI-driven PGT tools are also being developed to improve accuracy and reduce costs, potentially making genetic screening accessible to 90% of IVF patients by 2030.

Source: Read full article